Friday, October 30, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleSeeking Alpha· October 6, 2026

RPM projects fiscal 2027 mid-single-digit sales and adjusted EBITDA growth as Q2 raw material inflation rises to 9%–11%

View original at seekingalpha.com
RPM projects fiscal 2027 mid-single-digit sales and adjusted EBITDA growth as Q2 raw material inflation rises to 9%–11% Earnings Call Insights: RPM International (RPM) Q1 fiscal 2027 MANAGEMENT VIEW * “Our associates delivered record first quarter sales, adjusted EBITDA and adjusted EPS despite sluggish end markets and…
Opening lines of the source · Seeking Alpha · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • European sales growth is primarily driven by acquisition activity.

    60% confidence
  • The full-year guide carries significant uncertainty.

    60% confidence
  • RPM will probably do slightly better than dollar-for-dollar price/cost in Q2.

    60% confidence
  • Emerging markets growth is sustainable; they rose from slightly less than 5% of consolidated sales to 8%, and more acquisitions are expected.

    60% confidence
  • The warranty issue relates to a specific CPG business unit in Europe with a likely closure; no further warranty issues are anticipated.

    60% confidence
  • Q2 consolidated sales and EBITDA are expected to increase in the low to mid-single-digit range.

    60% confidence
  • Polyurethane feedstock shortages were more pronounced than expected and hurt sales; FIFO will impact the P&L.

    60% confidence
  • RPM will recover lost margin and probably more, and is highly confident it will meet or beat its 42% goal.

    60% confidence
  • RPM delivered record first quarter sales, adjusted EBITDA and adjusted EPS despite sluggish end markets and temporary operating headwinds; PCG and Consumer growth offset temporary CPG softness.

    60% confidence
  • Price is up about 2% across RPM, Q2 price is expected at 2.5% to 3.5%, and buybacks will continue.

    60% confidence
  • RPM aims to keep an investment-grade rating and has ample dry powder to repurchase shares; deal multiples are down 2 to 3 points.

    60% confidence
  • SG&A optimization actions offset gross margin pressure; gross margins fell 100 bps as raw material inflation outpaced pricing and MAP benefits.

    60% confidence
  • Emerging markets generated more than 20% revenue growth, and South American businesses were added to the Platform Group.

    60% confidence
  • The reduced full-year guide is a bet on when Construction Products Group and Tremco Roofing recover.

    60% confidence
  • FY2027 sales growth narrowed to mid-single-digit from 3%-7%, and adjusted EBITDA growth to mid-single-digit from 5%-10%.

    60% confidence
  • RPM expects no good news on Middle East conflict and has been selective in price increases.

    60% confidence
  • Consumer takeaway and foot traffic remain sluggish; results were driven by market share gains, new placements and improving results in The Pink Stuff.

    60% confidence
  • RPM returned $90.5 million to shareholders and total debt declined $263 million.

    60% confidence
  • Nothing has changed in September trends.

    60% confidence
  • Adjusted diluted EPS rose 5.3% to a first quarter record $1.98, driven by higher sales and MAP benefits, offset by raw material inflation, warranty expenses and bad debt expense.

    60% confidence
  • Q2 inflation is now expected at 9% to 11%, up from 6% to 8%, and additional pricing increases were implemented across all segments.

    60% confidence
  • Long term, rates and oil do not materially alter demand; RPM sees good work in tech, onshoring, manufacturing and data center build-out.

    60% confidence
  • CPG organic sales declined on a slowdown in education and health care markets and finished product shortages from supplier polyurethane constraints; several headwinds were temporary.

    60% confidence
  • Management now forecasts gross margin pressure for the year, versus moderating inflation in the second half expected on the Q4 call.

    60% confidence
  • The shortage issue is behind RPM in production, with inventory catch-up in Q2.

    60% confidence
  • UBS questioned whether RPM is having trouble getting pricing in CPG.

    60% confidence
  • Operating cash flow should grow on working capital improvement, and health care costs are flattening.

    60% confidence
  • CPG education and healthcare results and activity should improve in the second half; receivables from bankruptcies were written off but a significant amount may be recovered.

    60% confidence
  • PCG growth dynamics continue in Q2 and margin should improve through the year; PCG is driven by industrial capital spending and the platform approach.

    60% confidence
  • Freight costs are up meaningfully, leading to freight surcharges across a number of businesses.

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com